As President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, Andrew leads the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany.
Prior to this, Andrew served as Senior Vice President, Head of U.S. and Global MS Franchise, where he oversaw all commercial operations for the franchise in the US and also led global marketing efforts for our MS therapies.
In his 23 years with the company, Andrew Paterson has held positions in Local, Regional and Global commercial functions across a variety of therapeutic areas including Neurology, Endocrinology, Fertility and Cardio-vascular.
Andrew began his career with Merck KGaA, Darmstadt, Germany in 1998 as a Medical Sales Representative in the UK. He subsequently took on roles of increasing responsibility including first line Sales Manager, Marketing Manager and Business Unit Director. Global and Regional leadership roles followed. Most recently, his focus was on the preparation and execution of the global launch of a new therapy in MS and progressing pipeline therapies toward commercialization.
Andrew holds a BSc (Hons) in Biological Science from the University of Edinburgh and an Executive MBA from Ashridge Management College.